February’s top stories: Stryker's $1.28bn deal, IBM Watson's $2.6bn acquisition

Stryker buys Physio-Control International for $1.28bn, IBM Watson to acquire Truven Health Analytics from Veritas for $2.6bn. Medicaldevice-network.com wraps up the key headlines from February.


Stryker

Stryker signs agreement to acquire Physio-Control International for $1.28bn

Stryker signed a definitive agreement to buy Physio-Control International in a $1.28bn cash deal.

Founded in 1955, Physio-Control is a portfolio firm of Bain Capital Private Equity, and develops, manufactures and markets monitors/defibrillators, automated external defibrillators (AEDs) and CPR-assist devices besides providing data management and support services.

In 2011, Physio-Control was acquired by Boston's Bain Capital for $487m.

IBM Watson to buy Truven Health Analytics for $2.6bn

Truvnhealth

IBM Watson Health is planning to acquire US Cloud-based healthcare data provider Truven Health Analytics from Veritas Capital for around $2.6bn.

The acquisition will provide IBM Watson with around 8,500 clients, comprising US federal and state government agencies, employers, health plans, hospitals, clinicians and life science companies.

Truven Health is focused on providing analytic tools and services through brands such as MarketScan, 100 Top Hospitals, Advantage Suite, Micromedex, Simpler, ActionOI and JWA.

Macrogen and Silicon Biosystems to develop new genomic cancer assays

Silicon Biosystems Menarini entered a collaboration with South Korea-based Macrogen to develop new clinical assays and procedures for precision medicine in cancer.

As part of the deal, Silicon Biosystems' DEPArray digital-sorting technology will be combined with Macrogen's next-generation sequencing capabilities to develop tests certified under the Clinical Laboratory Improvement Amendments (CLIA) of 1988 by the Centers for Medicare & Medicaid Services (CMS) of the US.

The combination of Macrogen's whole-genome, whole-exome and targeted sequencing capabilities with the DEPArray's technology is expected to help resolve cellular heterogeneity of formalin-fixed paraffin-embedded (FFPE) biopsies and fine-needle aspiration (FNA) samples.

US FDA approves Boston's Acuity X4 quadripolar LV leads

Acuity

The US Food and Drug Administration (FDA) granted approval for Boston Scientific's Acuity X4 quadripolar left ventricular (LV) leads for use with its cardiac resynchronisation therapy (CRT) devices.

The company said that quadripolar leads are the wires that link CRT devices to the heart.

With approval, the company is now offering a full X4 CRT system in the US market, including the device and the leads.

FDA grants 510(k) clearance for CorMatrix's Tyke implantable device

The US Food and Drug Administration (FDA) granted 510(k) clearance for medical device firm CorMatrix Cardiovascular's Tkye implantable device, developed for neonate and infant cardiac tissue repair.

Tyke is a biomaterial technology based on the firm's ECM platform, and was developed to repair pericardial structures in neonates and infants.

The device can be used as an epicardial covering for damaged or repaired cardiac structures, as a patch material for intracardiac defects, septal defects and annulus repair, suture-line buttressing, and cardiac repair.

Luminex and University of São Paulo to validate Zika virus assay

Aedesaegypti

US-based Luminex collaborated with the University of São Paulo in Brazil to validate a multi-analyte Zika virus assay, developed by GenArraytion.

The MultiFLEX Mosquito-borne Panel, a qualitative nucleic acid assay, is currently available as a research-use only (RUO) multiplex panel designed to identify several disease agents such as the Zika virus.

Luminex is an exclusive distributor of GenArraytion's MultiFLEX Bioassays.

ResMed closes acquisition of medical device firm Inova Labs

US manufacturer ResMed completed the acquisition of Texas-based medical device firm Inova Labs, which is involved in developing oxygen therapy products.

Although initially announced last month January, the deal's terms have not been disclosed.

The deal allows ResMed to expand its care offerings and solutions to treat people with chronic obstructive pulmonary disease (COPD).

FDA approves Medtronic's MR-conditional cardiac defibrillators

The US Food and Drug Administration (FDA) granted approval for Irish firm Medtronic's magnetic resonance imaging (MRI) conditional cardiac resynchronisation therapy defibrillators (CRT-Ds) to treat heart failure.

The approved CRT-Ds, Amplia MRI Quad CRT-D SureScan and Compia MRI Quad CRT-D SureScan systems are designed to perform MRI scans on any part of the body without positioning restrictions.

According to the company, both CRT-D systems will be commercially available in the coming months and they will help patients treat their heart failure, as well as reducing their risk of sudden cardiac arrest.

TE Connectivity agrees to buy Ireland's Creganna Medical for $895m

Swiss manufacturer TE Connectivity signed an agreement to acquire Ireland-based Creganna Medical from Permira for around $895m.

Creganna designs and manufactures minimally invasive delivery and access devices, which can be used in a wide range of therapies.

The Irish company provides services to medical device original equipment manufacturers (OEMs) in around 30 countries worldwide.